Literature DB >> 29216679

The role of extracorporeal membrane oxygenator therapy in the setting of Type A aortic dissection.

Ibrahim Sultan1, Andreas Habertheuer2, Tyler Wallen2, Mary Siki2, Wilson Szeto2, Joseph E Bavaria2, Matthew Williams2, Prashanth Vallabhajosyula2.   

Abstract

BACKGROUND AND AIM: Patients presenting with type A aortic dissection (TAAD) present with a wide clinical spectrum ranging from hemodynamic stability to multiorgan malperfusion with cardiovascular collapse. Extracorporeal membrane oxygenator (ECMO) therapy is increasingly being utilized as salvage therapy in patients with acute cardiopulmonary failure and for post-cardiotomy shock. We sought to determine the utility of ECMO implementation post-TAAD repair.
METHODS: The Pennsylvania Health Care Cost Containment Council (PHC4) database, maintained by an independently functioning state agency, was retrospectively reviewed from 2004 to 2014. Patients with a primary diagnosis of aortic dissection requiring ECMO support during the same hospital visit were included in the analysis.
RESULTS: Thirty-nine patients were identified with diagnosis/procedure codes for TAAD repair and ECMO, of which four patients did not undergo TAAD repair. Of the remaining 35, 31 patients underwent open repair, and four patients underwent TEVAR. ECMO was instituted on the same day of TAAD surgery in 27 (69.2%) patients, and on post-operative day >1 in eight (20.5%) patients. Overall mortality in patients who were on ECMO the same day was 88.9% and 87.5% when it was done after the first post-operative day. All four patients with TAAD who underwent ECMO only died. Median time from ECMO implantation to death was 1.0 day.
CONCLUSIONS: Requirement for ECMO support in acute aortic dissection is associated with extremely high mortality irrespective of when the intervention is performed.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  aorta; extracorporeal membrane oxygenation; shock; type-a dissection

Mesh:

Year:  2017        PMID: 29216679     DOI: 10.1111/jocs.13245

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  7 in total

1.  Risk Factors for Postoperative Mortality in Patients with Acute Stanford Type A Aortic Dissection.

Authors:  Yan Huo; Hui Zhang; Bo Li; Kun Zhang; Bin Li; Shao-Han Guo; Zhen-Jie Hu; Gui-Jun Zhu
Journal:  Int J Gen Med       Date:  2021-10-21

2.  Renal hemodynamics by return cannular position of extracorporeal membrane oxygenation in swine.

Authors:  Hee Jung Kim; Seong Cheol Jeong; Jae Seung Jung; In Seup Kim; Choon-Hak Lim; Ho Sung Son
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

3.  Clinical outcomes of postoperative extracorporeal membrane oxygenation support in Stanford type a aortic dissection.

Authors:  Fudong Fan; Qing Zhou; Jun Pan; Hailong Cao; Kai Li; Yunxing Xue; Min Ge; Xuan Luo; Yang Chen; Dongjin Wang
Journal:  BMC Anesthesiol       Date:  2021-02-05       Impact factor: 2.217

4.  Commentary: Extracorporeal membrane oxygenation: Is it life-saving and cost effective for all patients?

Authors:  Harold L Lazar
Journal:  JTCVS Open       Date:  2020-03-03

5.  Veno-Arterial Extracorporeal Membrane Oxygenation for Patients Undergoing Acute Type A Aortic Dissection Surgery: A Six-Year Experience.

Authors:  Jun-Yi Hou; Chun-Sheng Wang; Hao Lai; Yong-Xin Sun; Xin Li; Ji-Li Zheng; Huan Wang; Jing-Chao Luo; Guo-Wei Tu; Zhe Luo
Journal:  Front Cardiovasc Med       Date:  2021-05-17

6.  The role of extracorporeal life support for patients with COVID-19: Preliminary results from a statewide experience.

Authors:  Ibrahim Sultan; Andreas Habertheuer; Asad A Usman; Arman Kilic; Eric Gnall; Michael E Friscia; Dmitriy Zubkus; Hitoshi Hirose; Pablo Sanchez; Olugbenga Okusanya; Wilson Y Szeto; Jacob Gutsche
Journal:  J Card Surg       Date:  2020-04-25       Impact factor: 1.620

7.  Commentary: Cerebral protection during aortic decannulation: Long run for a short slide?

Authors:  Derek Serna-Gallegos; Ibrahim Sultan
Journal:  JTCVS Tech       Date:  2020-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.